Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.63% |
| 2 | Technology | 13.19% |
| 3 | Consumer Discretionary | 10.53% |
| 4 | Financials | 8.74% |
| 5 | Communication Services | 7.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CTRA
2876
DELISTED
Coterra Energy
CTRA
| $541K | ﹤0.01% |
31,100
-49,000
| -61% | -$851K |
|
2877
Vanguard Morningstar Mid-Cap Growth ETF
VOT
$20.3B
| $540K | ﹤0.01% |
+3,400
| New | +$519K |
|
2878
PIMCO Investment Grade Corporate Bond Index Exchange-Traded Fund
CORP
$1.58B
| $539K | ﹤0.01% |
4,900
+2,500
| +104% | +$274K |
|
2879
Intellia Therapeutics
NTLA
$1.66B
| $538K | ﹤0.01% |
+36,700
| New | +$511K |
|
|
AUTL
2880
Autolus Therapeutics
AUTL
$591M
| $537K | ﹤0.01% |
40,700
-8,300
| -17% | -$109K |
|
|
NEPT
2881
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
| $530K | ﹤0.01% |
138
-26
| -16% | -$113K |
|
|
NH
2882
DELISTED
NantHealth, Inc
NH
| $529K | ﹤0.01% |
34,249
+7,507
| +28% | +$99.6K |
|
2883
Gentherm
THRM
$1.27B
| $528K | ﹤0.01% |
11,900
-55,864
| -82% | -$2.38M |
|
2884
Inuvo
INUV
$14.2M
| $527K | ﹤0.01% |
178,078
-1,120
| -0.6% | -$3.15K |
|
|
KWY
2885
Kingsway Corp
KWY
$283M
| $527K | ﹤0.01% |
283,133
+7,004
| +3% | +$14.7K |
|
2886
VanEck Junior Gold Miners ETF
GDXJ
$8.33B
| $524K | ﹤0.01% |
+12,400
| New | +$473K |
|
2887
STAAR Surgical
STAA
$1.26B
| $524K | ﹤0.01% |
+14,900
| New | +$492K |
|
|
SUPV
2888
Grupo Supervielle
SUPV
$738M
| $524K | ﹤0.01% |
+142,500
| New | +$426K |
|
2889
ZK International Group
ZKIN
$62.4M
| $521K | ﹤0.01% |
57,710
+128
| +0.2% | +$1.12K |
|
|
TLRA
2890
DELISTED
Telaria, Inc.
TLRA
| $521K | ﹤0.01% |
59,100
-318,600
| -84% | -$2.49M |
|
2891
Moog Inc Class B
MOG.B
$13B
| $518K | ﹤0.01% |
6,000
| – | – |
|
|
NCNA
2892
NuCana
NCNA
$6.16M
| $518K | ﹤0.01% |
17
+12
| +240% | +$406K |
|
2893
Pro-Dex
PDEX
$217M
| $515K | ﹤0.01% |
29,360
+100
| +0.3% | +$1.43K |
|
2894
iShares Global Infrastructure ETF
IGF
$10.7B
| $508K | ﹤0.01% |
+10,600
| New | +$498K |
|
2895
Lifetime Brands
LCUT
$219M
| $507K | ﹤0.01% |
73,000
-15,200
| -17% | -$109K |
|
|
PDS
2896
Precision Drilling
PDS
$1.06B
| $505K | ﹤0.01% |
18,103
+16,185
| +844% | +$371K |
|
2897
Sunoco
SUN
$14.2B
| $502K | ﹤0.01% |
+16,393
| New | +$516K |
|
|
ALR
2898
DELISTED
AlerisLife Inc
ALR
| $502K | ﹤0.01% |
135,382
+3,998
| +3% | +$19.2K |
|
|
TRQ
2899
DELISTED
Turquoise Hill Resources Ltd
TRQ
| $502K | ﹤0.01% |
68,194
-306,384
| -82% | -$1.58M |
|
2900
Value Line
VALU
$360M
| $500K | ﹤0.01% |
17,300
+1,000
| +6% | +$25.5K |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.